← All trials
NCT06112756
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 8, 2023
- Primary completion
- Aug 26, 2024
- Completion date
- Jan 7, 2025
- First posted
- Nov 1, 2023
- Last posted
- Nov 29, 2023
- Enrollment
- 78
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- BayerLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.